Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Not Applicable

Active, not recruiting

• Conditions: Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors; Hematologic Disease
• Interventions: Drug: Cellular Therapy

• Registration Number: NCT06849921
• Lead Sponsor: Ruijin Hospital

Brief Summary

This clinical trial aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory hematologic malignancies.

Detailed Description

This clinical trial aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory hematologic malignancies. The primary objective is to determine the maximum tolerated dose (MTD), safety profile, and the overall response rate (ORR) of CAR-T cells in these patients. Secondary objectives include assessing marrow remission rates and minimal residual disease (MRD) clearance at various time points (2 weeks, 1 month, 3 months, 6 months, and 1 year) in patients with bone marrow involvement, as well as evaluating the changes in multiple sites of involvement through PET-CT or PET-MRI before and one year after CAR-T therapy. The study will also track event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) rates at 1, 2, 3, and 5 years post-treatment.

Study Timeline

• Status Verified: 2024-11
• Study Start: 2024-11-07
• Study First Submitted: 2025-02-23
• Study First Submitted QC: 2025-02-23
• Last Update Submitted: 2025-02-23
• Study First Posted: 2025-02-27
• Last Update Posted: 2025-02-27
• Primary Completion: 2030-12-30
• Study Completion: 2030-12-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients with relapsed/refractory hematologic malignancies confirmed to express CD19, CD22, CD20, CD7, CD5, CD2, CD79b, BCMA, GPCR5D, CD38, CD33, CD123, CD133, CLL1, EBV (GP350, LMP1), CMV (Gb21, gB280...) or other validated targets (supported by domestic and international preclinical/clinical evidence) who meet the following criteria:

Male or female, aged ≥18 years and <75 years; Newly diagnosed patients with refractory disease (as defined by respective diagnostic criteria) after chemotherapy; Newly diagnosed patients with disease progression during chemotherapy and poor anticipated response to further chemotherapy; Patients with relapsed disease (≥1 recurrence) and confirmed residual tumor evidence; Patients with relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT); Patients with relapse after CAR-T therapy; Patients with hematologic malignancies deemed incurable by current surgical, radiotherapy, or chemotherapy interventions.

Exclusion Criteria

Patients meeting any of the following criteria will be excluded:

Life expectancy <12 weeks; Genetic testing reveals mutations or structural variants associated with the target antigens; Severe graft-versus-host disease (GVHD) requiring immunosuppressive therapy in post-HSCT relapse patients; Post-HSCT relapse <3 months with no available donor;

Organ dysfunction:

Serum creatinine >2.5 mg/dL; ALT/AST >5× upper limit of normal (ULN); Total bilirubin >2 mg/dL; Uncontrolled active infection; Active hepatitis B/C or HIV infection; Anticipated early loss to follow-up (<3 months post-treatment); Failure to provide signed informed consent or lack of ethics committee approval; Concurrent systemic conditions that may interfere with study participation; Other exclusion criteria deemed appropriate by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Precise Design of CAR-cell Injection	Cellular Therapy	The drug for this trial is Precise Designof CAR- cells transduced with the lentiviral vector . The dose is 2x10e6 \~1x10e7 CAR-cell/kg in patients with relapsed/refractory hematologic malignancies.

Primary Outcome Measures

Name	Time	Method
adverse events.	1 month	Type, incidence and severity of adverse events
Maximum tolerated dose	1 month	The maximum dose that does not cause death of the subject
Overall response rate	3 months	ORR in patients is defined as the rate of complete remission (CR, CRh)

Secondary Outcome Measures

Name	Time	Method
Overall incidence and severity of adverse events.	12 months	Overall incidence and severity of adverse events will measure in this trial.
Rate of relapse and refractory of Hematologic Diseases patients achieving MRD negative CR	12 months	The rate of relapse and refractory of Hematologic Diseases patients achieving MRD negative CR in D28; 3,6,12months.

Trial Locations

Locations (1)

Ruijin Hospital, Shanghai Jiaotong University School of Medicine; 🇨🇳 Shanghai, Shanghai, China